Table 3.
The characteristics of included studies about the NK cells activating receptors and their ligands.
| Marker | Author | Year | Country | Sample size | Measure ment | Treatment | Source | Tumor stage | VS | Number of VS | Divide | Outcome | P-value | Follow-up times | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Activating receptors of the NK cells | NKp30 | Chew et al. (41) | 2010 | Singapore | 61 | Immuno histochemistry | resection | Intratumor | I-III | High/Low | NA | median | OS | HR (95%CI) 0.34 (0.13,0.85) P=0.0144 | median: 2.56 (0.02-9.11) year |
| NKp30 | Li et al. (42) | 2021 | China | 25 | Flow cytometry | untreated | Peripheral blood | NA | High/Low | 16/9 | cutoff value | OS;PFS | Log-rank test P=0.279; Log-rank test P=0.016 | NA | |
| NKG2D | Gao et al. (23) | 2016 | China | 20 | Flow cytometry | resection | Peripheral blood | I-III | High/Low | 10/10 | median | OS;RFS | Log-rank test P=0.014; Log-rank test P=0.010 | until:2014.11 | |
| NKp30 | Rochigneux et al. (43) | 2019 | France | 57 | Flow cytometry | RFA | Peripheral blood | NA | High/Low | 28/29 | median | PFS | HR (95%CI) 0.61 (0.29,1.29) P=0.20 | until:12/2016 | |
| Ligands of the NK cells activating receptors | soluble MICA | Li et al. (44) | 2013 | China | 60 | ELISA | TACE | serum | III/IV | High/Low | 28/32 | median | OS | HR (95%CI) 1.47 (1.01,1.95) P<0.001 | until:31/08/2010 |
| B7-H6 | Qiu et al. (45) | 2021 | China | 90 | Immuno histochemistry | resection | Intratumor | I/II | High/Low | 33/57 | mean-H score | OS;DFS | HR (95%CI) 0.47 (0.24,0.93) P=0.029; HR (95%CI) 0.72 (0.36,1.43) P=0.1013 | total:>60 month | |
| MICA | Zhang et al. (28) | 2014 | China | 143 | Immuno histochemistry | resection | Intratumor | I-IV | High/Low | NA | NA | OS;RFS | HR (95%CI) 0.91 (0.49,1.69) P=0.774; HR (95%CI) 1.43 (0.90,2.27) P=0.135 | until:08/2013 | |
| MICA/B | Fang et al. (46) | 2014 | China | 96 | Immuno histochemistry | resection | Intratumor | I-IV | High/Low | 75/21 | MICA/B expression score | OS | HR (95%CI) 0.32 (0.11,0.92) P<0.001 | until:08/2012 | |
| ULBP1 | Kamimura et al. (47) | 2012 | Japan | 54 | Immuno histochemistry | untreated/ resection | Intratumor | NA | Positive/Negative | 25/47 | expression | OS;RFS | HR (95%CI) 0.72 (0.09,5.70) P=0.120; HR (95%CI) 0.2 (0.06,0.65) P=0.006 | NA | |
| ULBP1 | Easom et al. (48) | 2020 | England | 72 | ELISA | untreated | serum | NA | High/Low | NA | NA | OS | HR (95%CI) 2.11 (1.02,4.02) P=0.0029 | NA |
NK, Natural killer; CI, Confidence interval; HR, Hazard ratio; RFA, Radiofrequency ablation; ELISA, Enzyme-linked immunosorbent assay; TACE, Transcatheter arterial chemoembolization; OS, Overall survival; DFS, Disease-free survival; RFS, Recurrence-free survival; PFS, Progression-free survival; NA, Not available.